Related Experiment Video

Updated: Jul 4, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
11:17

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

Individualization of growth hormone therapy

L B Johnston1

  • 1Centre of Endocrinology, William Harvey Research Institute, Queen Mary School of Medicine and Dentistry, London, UK. l.b.johnston@qmul.ac.uk

Best Practice & Research. Clinical Endocrinology & Metabolism
|June 10, 2008
PubMed

Insights

Children born small for gestational age often experience short stature. Individualized growth hormone therapy, guided by prediction models, can improve height outcomes.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Genetics

Background:

  • Small for gestational age (SGA) births affect a significant portion of children with short stature.
  • SGA children require thorough assessment for underlying conditions and neurodevelopmental issues.
  • Growth hormone (GH) therapy is a key treatment for short stature in SGA children.

Purpose of the Study:

  • To highlight the importance of individualized treatment for short stature in SGA children.
  • To discuss the role of prediction models in optimizing GH therapy.
  • To identify factors influencing treatment response in SGA children.

Main Methods:

  • Review of randomized controlled trials (RCTs) on GH therapy in SGA children.
  • Analysis of prediction models for GH therapy outcomes.
  • Identification of modifiable and non-modifiable factors affecting treatment.

Main Results:

  • GH therapy demonstrates significant growth acceleration in childhood and improved adult height in SGA children.
  • Prediction models enable personalized GH dosing and treatment initiation timing.
  • Factors like target height, weight SDS, and initial treatment response influence outcomes.

Conclusions:

  • Individualized GH therapy, informed by prediction models, is crucial for optimizing height outcomes in SGA children.
  • Understanding modifiable and non-modifiable factors allows for tailored treatment strategies.
  • Early intervention and personalized approaches are key to addressing short stature in SGA populations.

More Related Videos

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy12:04

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy

Published on: August 14, 2012

Related Concept Videos

Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...